Concert Pharma (CNCE) Tops Q4 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. DOX
8. INSP
9. HNGE
10. AMD

Go back to Concert Pharma (CNCE) Tops Q4 EPS by 7c

Concert Pharmaceuticals Reports Year Ended 2016 Financial Results

March 6, 2017 7:15 AM EST

- Vertex Pharmaceuticals to Acquire Cystic Fibrosis Candidate, CTP-656, from Concert Pharmaceuticals for up to $250 Million -

- CTP-543 On Track to Advance Into Phase 2a Trial -

- Conference Call Scheduled Today at 8:30 a.m. EST -

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:... More

Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis

March 6, 2017 7:00 AM EST

-Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF-

-Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase... More